RPRX
Royalty Pharma plc
49.38
17 x 49.12
17 x 49.56
bid
ask
-
0.26
0.52%
17 @ 04:00 PM
49.13 -0.25 (0.51%)
| Ytd | 27.80% | |
| 1y | 54.17% |
49.20
day range
49.91
32.03
52 week range
50.00
| Open | 49.64 | Prev Close | 49.64 | Low | 49.20 | High | 49.91 | Mkt Cap | 29.27B |
| Vol | 1.91M | Avg Vol | 3.40M | EPS | 1.78 | P/E | 27.74 | Forward P/E | 8.98 |
| Beta | 0.39 | Short Ratio | 3.34 | Inst. Own | 84.59% | Dividend | 0.94 | Div Yield | 1.89 |
| Ex Div Date | 05-15 | Earning | 05-06 | 50-d Avg | 46.78 | 200-d Avg | 40.14 | 1yr Est | 52.44 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-05-06 | 2026-03 | 1.22 | N/A | N/A | N/A |
| 2026-02-11 | 2025-12 | 1.33 | 1.46 | 0.13 | 9.77% |
| 2025-11-05 | 2025-09 | 1.11 | 1.17 | 0.06 | 5.41% |
| 2025-11-05 | 2025-09 | 1.11 | N/A | N/A | N/A |
| 2025-08-06 | 2025-06 | 1.1 | 1.14 | 0.04 | 3.64% |
| 2025-08-06 | 2025-06 | 1.1 | N/A | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-04-21 | UBS | Upgrade | Buy | Buy |
| 2026-04-10 | Morgan Stanley | Upgrade | Overweight | Overweight |
| 2026-01-27 | Citigroup | Upgrade | Buy | Buy |
| 2025-12-11 | TD Cowen | Upgrade | Buy | Buy |
| 2025-10-10 | Morgan Stanley | Upgrade | Overweight | Overweight |
| 2025-09-30 | Goldman Sachs | Upgrade | Buy |
Profile
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases. The company was founded in 1996 and is based in New York, New York.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-03-30 | BASSLER BONNIE L | Director | 73.95K | Stock Award(Grant) |
| 2026-03-31 | COYNE TERRANCE P | Chief Financial Officer | 0.00 | Sale |
| 2025-05-12 | DESOUZA ERROL B | Director | 81.35K | Stock Award(Grant) |
| 2025-05-12 | ENGELBERT CATHERINE M. | Director | 51.13K | Stock Award(Grant) |
| 2025-06-29 | FERNANDEZ HENRY A | Director | 123.52K | Stock Award(Grant) |
| 2026-02-10 | HITE CHRISTOPHER D. | Officer | 0.00 | Stock Award(Grant) |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2025-12-30 | Morgan Stanley | 55.27M | 2.73B | 12.44% |
| 2025-12-30 | Capital International Investors | 31.10M | 1.54B | 7.00% |
| 2025-12-30 | FMR, LLC | 26.27M | 1.30B | 5.91% |
| 2025-12-30 | Blackrock Inc. | 26.19M | 1.29B | 5.89% |
| 2025-12-30 | BAILLIE GIFFORD & CO | 17.01M | 839.89M | 3.83% |
| 2025-12-30 | Swedbank AB | 11.94M | 589.70M | 2.69% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | NEW PERSPECTIVE FUND | 19.65M | 970.11M | 4.42% |
| 2025-12-30 | MORGAN STANLEY INSTITUTIONAL FUND INC-GROWTH PORTFOLIO | 5.50M | 271.81M | 1.24% |
| 2025-12-30 | GROWTH FUND OF AMERICA | 4.39M | 216.57M | 0.99% |
| 2026-01-30 | Capital Income Builder | 4.22M | 208.38M | 0.95% |
| 2025-12-30 | VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 4.05M | 199.93M | 0.91% |
| 2025-12-30 | Victory Portfolios II-VictoryShares Free Cash Flow ETF | 3.85M | 190.34M | 0.87% |
Dividend
| Dividend | Date |
|---|---|
| 0.235 | 2026-05-15 |
| 0.235 | 2026-02-20 |
| 0.22 | 2025-11-14 |
| 0.22 | 2025-08-15 |
| 0.22 | 2025-05-16 |
| 0.22 | 2025-02-21 |
Split
| Split | Date |
|---|---|
| 0.25 : 1 | 2010-10-15 |
